News Grail cancer test gets lukewarm backing from FDA adcomm FDA expert advisors voted in favour of Grail's Galleri blood test for detecting multiple cancers, but some expressed misgivings about its efficacy.
News Grail multi-cancer test taps into Hims & Hers network Grail has teamed up with telehealth company Hims & Hers to boost access to its recently filed Galleri blood test for cancer screening.
News ESMO: Grail's data on cancer blood test firms up Data from a new phase 3 trial of Grail's blood test for multiple cancers show improved efficacy and a lower rate of false alarms than a prior study.
News Grail plans FDA filing for cancer blood test after new trial Grail is eyeing FDA approval of its Galleri cancer screening blood test after a second positive phase 3 trial.
News Illumina fined €432m for ignoring Grail merger objection The European Commission has levied a substantial penalty on DNA sequencing giant Illumina for closing its takeover of cancer detection company Grail without EU regulatory
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.